We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study (Bo-CRISP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01843361
First Posted: April 30, 2013
Last Update Posted: April 30, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Saskia Meves, Ruhr University of Bochum
April 26, 2013
April 30, 2013
April 30, 2013
July 2010
December 2012   (Final data collection date for primary outcome measure)
Result of platelet function test [ Time Frame: one day ]
Aggregometry result of antiplatelet therapy
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study
Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with an acute ischemic stroke admitted to our stroke unit and treated with clopidogrel
Ischemic Stroke
Not Provided
acute ischemic stroke
Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
159
December 2012
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • acute ischemic stroke
  • admittance to stroke unit
  • clopidogrel medication

Exclusion Criteria:

  • no consent
  • prior bleeding disorders
  • severe liver disorders
  • current gastrointestinal disorders
  • congestive heart failure
  • life-threatening malignancies
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01843361
Meves-clopi-01
No
Not Provided
Not Provided
Saskia Meves, Ruhr University of Bochum
Ruhr University of Bochum
Not Provided
Principal Investigator: Saskia H Meves, MD Ruhr University Bochum, Department of Neurology
Ruhr University of Bochum
April 2013